Disease progression model for cognitive deterioration from Alzheimer's Disease Neuroimaging Initiative database

被引:95
作者
Ito, Kaori [1 ]
Corrigan, Brian [1 ]
Zhao, Qinying [1 ]
French, Jonathan [1 ]
Miller, Raymond [1 ]
Soares, Holly [1 ]
Katz, Elyse [1 ]
Nicholas, Timothy [1 ]
Billing, Bill [1 ]
Anziano, Richard [1 ]
Fullerton, Terence [1 ]
机构
[1] Pfizer Global Res & Dev, New London, CT USA
关键词
Disease progression model; Natural history; ADAS-cog; MCI; Alzheimer's disease; Age; APOE epsilon 4 genotype; CLINICAL PREDICTORS; RISK-FACTORS; IMPAIRMENT; DEMENTIA; DECLINE; SEX; AGE;
D O I
10.1016/j.jalz.2010.03.018
中图分类号
R74 [神经病学与精神病学];
学科分类号
100204 [神经病学];
摘要
Background: A mathematical model was developed to describe the longitudinal response in Alzheimer's Disease Assessment Scale-cognitive (ADAS-cog) obtained from the Alzheimer's Disease Neuroimaging Methods: The model was fit to the longitudinal ADAS-cog scores from 817 patients. Risk factors (age, apolipoprotein epsilon 4 [APOE epsilon 4] genotype, gentler, family history of AD, years of education) and baseline severity were tested as covariates. Results: Rate of disease progression increased with baseline severity. Age, APOE epsilon 4 genotype, and gender were identified as potential covariates influencing disease progression. The rate of disease progression in patients with mild to moderate AD was estimated as approximately 5.5 points/yr. Conclusions: A disease progression model adequately described the natural decline of ADAS-cog observed in Alzheimer's Disease Neuroimaging Initiative. Baseline severity is an important covariate to predict a curvilinear rate of disease progression in normal elderly, mild cognitive impairment, and AD patients. Age, APOE epsilon 4 genotype, and gender also influence the rate of disease progression. (C) 2011 The Alzheimer's Association. All rights reserved.
引用
收藏
页码:151 / 160
页数:10
相关论文
共 27 条
[1]
Annual rate and predictors of conversion to dementia in subjects presenting mild cognitive impairment criteria defined according to a population-based study [J].
Amieva, H ;
Letenneur, L ;
Dartigues, JL ;
Rouch-Leroyer, I ;
Sourgen, C ;
D'Alchée-Birée, F .
DEMENTIA AND GERIATRIC COGNITIVE DISORDERS, 2004, 18 (01) :87-93
[2]
Modeling the time-course of Alzheimer dementia. [J].
Ashford J.W. ;
Schmitt F.A. .
Current Psychiatry Reports, 2001, 3 (1) :20-28
[3]
Baseline cognitive function predicts rate of decline in basic-care abilities of individuals with dementia of the Alzheimer's type [J].
Atchison, Timothy B. ;
Massman, Paul J. ;
Doody, Rachelle S. .
ARCHIVES OF CLINICAL NEUROPSYCHOLOGY, 2007, 22 (01) :99-107
[4]
BEAL SL, 1989, NONMEM USERS GUIDES8
[5]
To what degree does cognitive impairment in Alzheimer's disease predict dependence of patients on caregivers? [J].
Caro, Jaime ;
Ward, Alexandra ;
Ishak, Khajak ;
Migliaccio-Walle, Kristen ;
Getsios, Denis ;
Papadopoulos, George ;
Torfs, Koen .
BMC NEUROLOGY, 2002, 2 (1)
[6]
Drug treatment effects on disease progression [J].
Chan, PLS ;
Holford, NHG .
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 2001, 41 :625-659
[7]
APOE ε4 allele predicts faster cognitive decline in mild Alzheimer disease [J].
Cosentino, S. ;
Scarmeas, N. ;
Helzner, E. ;
Glymour, M. M. ;
Brandt, J. ;
Albert, M. ;
Blacker, D. ;
Stern, Y. .
NEUROLOGY, 2008, 70 (19) :1842-1849
[8]
The Alzheimer's disease assessment scale: Patterns and predictors of baseline cognitive performance in multicenter Alzheimer's disease trials [J].
Doraiswamy, PM ;
Bieber, F ;
Kaiser, L ;
Krishnan, KR ;
ReuningScherer, J ;
Gulanski, B .
NEUROLOGY, 1997, 48 (06) :1511-1517
[9]
Population pharmacokinetic modeling: The importance of informative graphics [J].
Ette, EI ;
Ludden, TM .
PHARMACEUTICAL RESEARCH, 1995, 12 (12) :1845-1855
[10]
Sex, apolipoprotein E ε4 status, and hippocampal volume in mild cognitive impairment [J].
Fleisher, A ;
Grundman, M ;
Jack, CR ;
Petersen, RC ;
Taylor, C ;
Kim, HT ;
Schiller, DHB ;
Bagwell, V ;
Sencakova, D ;
Weiner, MF ;
DeCarli, C ;
DeKosky, ST ;
van Dyck, CH ;
Thal, LJ .
ARCHIVES OF NEUROLOGY, 2005, 62 (06) :953-957